Submit a Letter to the Editor for:
Eui-Cheol Shin, Ulrike Seifert, Takanobu Kato, Charles M. Rice, Stephen M. Feinstone, Peter-M. Kloetzel, Barbara Rehermann
J Clin Invest. 2006;
116(11):3006
doi:10.1172/JCI29832
Abstract |
Full text
|
PDF
|
Supplemental material
I
FN-γ is known as the initial and primary inducer of immunoproteasomes during viral infections. We now report that type I IFN induced the transcription and translation of immunoproteasome subunits, their incorporation into the proteasome complex, and the generation of an immunoproteasome-dependent CD8 T cell epitope in vitro and provide in vivo evidence that this mechanism occurs prior to IFN-γ responses at the site of viral infection. Type I IFN–mediated generation of immunoproteasomes was initiated by either poly(I:C) or HCV RNA in human hepatoma cells and was inhibited by neutralization of type I IFN. In serial liver biopsies of chimpanzees with acute HCV infection, increases in immunoproteasome subunit mRNA preceded intrahepatic IFN-γ responses by several weeks, instead coinciding with intrahepatic type I IFN responses. Thus, viral RNA–induced innate immune responses regulate the antigen-processing machinery, which occurs prior to the detection of IFN-γ at the site of infection. This mechanism may contribute to the high effectiveness (95%) of type I IFN–based therapies if administered early during HCV infection.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
